OncoMatch/Clinical Trials/NCT05821088
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Is NCT05821088 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for recurrent b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classic hodgkin lymphoma.
Treatment: Carboplatin · Etoposide · Ifosfamide · Lenalidomide · Tafasitamab — This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refractory). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide may have antineoplastic activity which may help block the formation of growths that may become cancer. Drugs used in chemotherapy, such as carboplatin, etoposide and ifosfamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tafasitamab and lenalidomide followed by ICE may be a better treatment for patients with relapsed or refractory large B-cell lymphomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: BCL2 rearrangement
Allowed: BCL6 rearrangement
Allowed: MYC rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemo-immunotherapy (cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine)
Have received one line of prior chemo-immunotherapy (i.e. cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine [R-CHOP])
Cannot have received: hematopoietic cell transplant
Prior hematopoietic cell transplant
Cannot have received: solid organ transplant
Prior solid organ transplant
Cannot have received: anti-CD19 targeted therapy
Prior treatment with anti-CD19 targeted therapy
Cannot have received: immunomodulatory agent (lenalidomide)
Prior treatment with ... lenalidomide
Lab requirements
Blood counts
Absolute neutrophil count >= 1000 / mcL; Platelets >= 75,000 / mcL in absence of transfusion support within 7 days of determining eligibility; Hemoglobin >= 8.0 g/dL, with exception of cases in which cytopenias are due to marrow involvement by lymphoma
Kidney function
Serum creatinine clearance >= 60 mL/min (calculated according to institutional standard)
Liver function
Serum total bilirubin <= 1.5 x ULN (except in patients with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dL); AST and ALT <= 3.0 x ULN
Absolute neutrophil count >= 1000 / mcL; Platelets >= 75,000 / mcL ...; Hemoglobin >= 8.0 g/dL ...; Serum total bilirubin <= 1.5 x ULN ...; AST and ALT <= 3.0 x ULN; Serum creatinine clearance >= 60 mL/min ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify